Mabil
Analyst
Jefferies
Equibles does not estimate personal net worth.
About Mabil
Mabil is recorded as Analyst at Jefferies. Mabil has spoken on 2 earnings calls across 2 companies, most recently for CytomX Therapeutics, Inc. on May 7, 2026. Those appearances were for CytomX Therapeutics, Inc. (CTMX) and Alx Oncology Holdings Inc (ALXO). The companies whose calls Mabil spoke on are classified in the Healthcare sector.
Mabil on recent calls
“So just on the 8.6 versus 10 mg per kg, just a little bit curious if you could maybe give some color on the dose decision logic because we saw the headline OR, 32% versus 20%.”
“Maybe this was asked, but I wanted to ask, again, Is that IHC cutoff for Aspen 9 primary endpoint already locked in, or could you maybe talk about those pre-specified decision rules we're using to select that cut point?”
Affiliation history
-
Jefferies
Analyst
Transcript header (unverified)
Current